Cordarone Intravenous (Cordarone I.V.) Nursing offspring of lactating rats administered amiodarone have demonstrated reduced viability and reduced body weight gains. (900 mg) to 500 mL D 5 W (concentration = 1.8 mg/mL). infusions exceeding 2 hours must be administered in glass or polyolefin bottles containing DIt is well known that amiodarone adsorbs to polyvinyl Cordarone I.V. 150 mg over the FIRST 10 minutes (15 mg/min). already administered, as well as the bioavailability of oral Cordarone. Applies to the following strengths: 50 mg/mL; 200 mg; 300 mg; 100 mg; 400 mg; 150 mg/150 mL-D0.5%; 900 mg/500 mL-D5%; 450 mg/250 mL-D5%; 150 mg/100 mL-D5%; 360 mg/200 mL-D5%This drug should be used at the lowest effective dose in order to prevent the occurrence of side effects.US BOXED WARNINGS (TABLET): These effects may also be seen with IV administration.Administration advice: The manufacturer product information should be consulted.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Carefully monitor patients receiving amiodarone for evidence of progressive hepatic injury. -Supplemental infusions: 150 mg over 10 minutes (15 mg/min) for breakthrough episodes of ventricular fibrillation (VF) or hemodynamically unstable ventricular tachycardia (VT) Maximum dose: Initial infusion rate: 30 mg/min Duration of therapy: Until ventricular arrhythmias stabilize (most patients require 48 to 96 hours); maintenance infusion of up to 0.5 mg/min can be continued for up to 3 weeks. must be delivered by a volumetric infusion pump. contains polysorbate 80, which is known to leach di-(2-ethylhexyl)phthalate (Cordarone I.V. The optimal dose for changing from intravenous to oral administration of amiodarone will depend on the dose of intravenous amiodarone already administered, as well as the bioavailability of oral amiodarone. DOSE RECOMMENDATIONS FIRST 24 HOURS The first 24-hour dose may be individualized for each patient; however, in controlled Based on the experience from clinical studies of Cordarone I.V., a maintenance infusion of up to 0.5 mg/min can be cautiously continued for 2 to 3 weeks regardless of the patients age, The surface properties of solutions containing injectable amiodarone are altered such that the drop size may be reduced. (amiodarone HCl) is available in packages of 10 ampuls (2 cartons each containing 5 ampuls), 3 mL each, as follows: In a total of 1836 patients in controlled and uncontrolled The most important treatment-emergent adverse effects were The following table lists the most common (incidence 2%) treatment-emergent adverse events during Cordarone I.V. There have been reports of death associated with amiodarone-induced thyrotoxicosis.

Monitor the initial rate of infusion closely and do not exceed the recommended rate [see Dosage and Administration (Table 5: ADVERSE REACTIONS IN PATIENTS RECEIVING INTRAVENOUS AMIODARONE IN CONTROLLED AND OPEN-LABEL STUDIES (≥ 2% INCIDENCE) Amiodarone is metabolized to the active metabolite desethylamiodarone (DEA) by the cytochrome P450 (CYP450) enzyme group, specifically CYP3A and CYP2C8. The delayed ossification was reversible and related to decreased fetal weight. Cases of severe hypothyroidism and myxedema coma, sometimes fatal, have been reported in association with amiodarone therapy. The risk of exposing the infant to amiodarone must be weighed against the potential benefit of arrhythmia suppression in the mother. One should infuse this 100 mL over 10 minutes (15 mg/min) for a total of 150 mg. Identify hyperthyroidism by relevant clinical signs and symptoms, subnormal serum levels of thyroid stimulating hormone (TSH), abnormally elevated serum free T4, and elevated or normal serum T3.

7. Hyperthyroidism may also result from direct amiodarone-induced destructive thyroiditis that occurs in individuals with no underlying thyroid disease (type 2 AIT), resulting in the release of preformed thyroid hormone into the bloodstream from damaged thyroid follicular epithelium.

Intravenous amiodarone administration prolongs intranodal conduction (Atrial-His, AH) and refractoriness of the atrioventricular node (ERP AVN), but has little or no effect on sinus cycle length (SCL), refractoriness of the right atrium and right ventricle (ERP RA and ERP RV), repolarization (QTc), intraventricular conduction (QRS), and infra-nodal conduction (His-ventricular, HV).

Cordarone-induced hyperthyroidism may result in thyrotoxicosis and/or the possibility of arrhythmia breakthrough or aggravation. administration. is contraindicated in patients with known hypersensitivity to any of the components of Cordarone I.V., including Amiodarone is generally considered a class III antiarrhythmic drug, but it possesses Cordarone I.V. There have been reports of early development of pulmonary fibrosis (within 1 to 3 months) following initiation of amiodarone treatment. Infuse 200 mL at a rate of 0.556 mL/min. Add 3 mL of Cordarone I.V. Cordarone-induced hyperthyroidism may result in thyrotoxicosis and/or the possibility of arrhythmia breakthrough or aggravation.